Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

PHASE3RecruitingINTERVENTIONAL

Enrollment

765

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions

Chronic Stable Angina Pectoris

Interventions

DRUG

T89 capsule

T89 capsules (75mg)

DRUG

Placebo capsule

Placebo capsules (0mg)

Trial Locations (1)

RECRUITING

Southwest Florida Research LLC, Naples

All Listed Sponsors

lead

Tasly Pharmaceuticals, Inc.

INDUSTRY